Novo Nordisk has licensed Nanexa’s PharmaShell drug-delivery technology in a deal worth more than €1bn, sending the Swedish firm’s shares up over 100%.
Novo gets an exclusive licence to use PharmaShell for certain therapeutic peptide drugs, including treatments for obesity and type 2 diabetes. Novo will lead development and commercialisation.
The deal at a glance
- Value: More than €1bn in upfront and milestone payments combined
- Royalties: Low single-digit royalties on future sales
- Rights: Exclusive licence for certain therapeutic peptides, including for obesity and type 2 diabetes
- Lead: Novo Nordisk leads development and commercialisation
- Market reaction: Nanexa shares more than doubled, reaching their highest level in more than five years
What PharmaShell does
PharmaShell is Nanexa’s drug-delivery platform. It is designed to coat drug particles so medicines can be released more slowly in the body. For peptide drugs, that could mean injections are needed less often.
Why it matters
- Delivery technology is valuable. In obesity and diabetes, how a drug is delivered matters almost as much as the drug itself. Longer intervals between doses could set products apart.
- Small company, big partner. For Nanexa, a licence with the market leader validates its platform.
- Undisclosed upfront. The upfront payment was not separated from the milestone total, so the guaranteed amount is unclear.
What it means for the supply chain
Longer-acting formulations could reduce the number of doses patients need. Over time, that could ease pressure on pens, cartridges and fill-finish capacity, which have been under strain from obesity drug demand. Device and packaging suppliers should watch how far longer-acting peptides progress.
The bottom line
Novo’s licence turns Nanexa into a key partner in the obesity market. The full value depends on milestones, but the market’s reaction shows how much investors prize delivery technology in this space.
Frequently Asked Questions
What did Novo Nordisk license from Nanexa? An exclusive licence to use Nanexa’s PharmaShell drug-delivery technology for certain therapeutic peptides, including for obesity and type 2 diabetes.
How much is the deal worth? More than €1bn in combined upfront and milestone payments, plus low single-digit royalties.
How did Nanexa’s shares react? They more than doubled, reaching their highest level in more than five years.
Who leads development? Novo Nordisk leads development and commercialisation.
Sources
| Source | Used for |
|---|---|
| Hargreaves Lansdown news (company announcement coverage) | Deal value, licence scope, royalties and share movement |
| CNBC | Market reaction |
| Ground News aggregation of deal coverage | Deal value reporting |
Additional Resources
| Resource | What you’ll find |
|---|---|
| Novo Nordisk investor relations | Obesity and diabetes portfolio updates |
| Nanexa investor relations | PharmaShell platform information |
| European Medicines Agency (EMA) | Regulation of peptide medicines |
| World Health Organization (WHO) | Global obesity and diabetes data |
Data note: Reports gave inconsistent euro and pound figures for the deal, so it is described as “more than €1bn”. The upfront payment was not disclosed separately.